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Background:  Evaluation of risk in stable coronary artery disease (CAD) is currently based on clinical characteristics and biomarkers of 
dysglycemia, dyslipidemia, renal dysfunction, and inflammatory activity. In the STABILITY trial, treatment with darapladib, an inhibitor of 
lipoprotein-associated phospholipase A2, in 15,828 patients with stable CAD did not significantly reduce major adverse cardiovascular 
events (MACE=cardiovascular (CV) death, myocardial infarction (MI) or stroke) but reduced major coronary events (MCE=coronary death, 
MI, urgent coronary revascularization) by 10% compared to placebo (nominal p=0.045). We investigated the prognostic value of GDF-15, a 
biomarker of oxidative stress and cellular aging, on CV outcomes.
methods:  The level of GDF-15 was measured in serum samples from 14,577 patients at randomization. Relations between GDF-15 and 
CV events during 3.7 years were evaluated by Cox regression adjusting for randomized treatment, age, sex, smoking, BMI, hypertension, 
diabetes, previous MI, previous CABG, multivessel CAD, polyvascular disease and renal dysfunction.
results:  The event rates were stable over time. Higher levels of GDF-15 were independently related to higher rates of CV outcomes 
regardless of clinical background factors and study treatment.
 
Conclusion:  In patients with stable CAD, GDF-15 provides additional prognostic information on CV death, MI, stroke and major coronary 
events and might be a useful complement in risk assessment.
